Skip to Main Content

Chapter 37: Thyroid Cancer

Ann Gramza; Sam Wells

INTRODUCTION

Epidemiology

|Download (.pdf)|Print
Epidemiology
Incidence: 62,980 (male: 15,190; female: 47,790. Estimated new cases for 2014 in the United States) (6.1 per 100,000 males 18.2 per 100,000 females)
Deaths: Estimated 1,890 in 2014 (male: 830; female: 1,060)
Median age: 50 years
Male to female ratio: 1:3

  • One of the few cancers that has increased in incidence over the past several years

  • Sixth most common cancer in women

  • The number of new diagnoses is about double the number from 10 years ago

  • Mainly affects young people. Nearly 2 of 3 cases are found in people between the ages of 20 and 55 years

 

Siegel R et al. CA Cancer J Clin 2014;64:9–29

Surveillance, Epidemiology and End Results (SEER) Program, available from http://seer.cancer.gov (accessed in 2013)

Pathology

|Download (.pdf)|Print
Pathology
Epithelial Carcinomas Incidence Other Cell Types Incidence
Papillary carcinomas 75% Medullary carcinoma <8%
Usual papillary (75) Anaplastic carcinomas✫ 2%
Follicular variant (15) Lymphoma Very rare
Tall cell variant (4) Angiomatoid neoplasms Very rare
Columnar cell variant (<1) Mucoepidermoid carcinomas Very rare
Diffuse sclerosing variant (3) Malignant adult thyroid teratomas Very rare
Oxyphilic (Hürthle cell) variant (2) Carcinomas with thymic features Very rare
Follicular carcinomas 10% Paragangliomas Very rare
Usual follicular (76)    
Oxyphilic (Hürthle cell) variant (20)    
Insular carcinoma (4)    

 

✫Evolved from papillary or follicular

Ain KB. Rev Endocr Metab Disord 2000;1:225–231

LiVolsi VA. Surgical Pathology of the Thyroid. Philadelphia, PA: WB Saunders, 1990

 

Papillary thyroid cancer (PTC)

  1. Develops from the follicular cells in the normal thyroid

  2. Usually found in 1 lobe; only 10–20% appear in both lobes

  3. Considered a differentiated thyroid cancer

  4. Together with follicular thyroid cancer, accounts for 80–90% of all thyroid cancers

  5. Mutations in BRAF have been reported in 60–80% of patients with V600E (T1799A), the most common mutation

 

Follicular thyroid cancer (FTC)

  1. Less common than PTC

  2. Develops from the follicular cells in the normal thyroid

  3. Considered a differentiated thyroid cancer

  4. Together with PTC, accounts for 80–90% of all thyroid cancers

  5. Hürthle cell carcinoma is usually assumed to be a variant of FTC, although its prognosis is worse

  6. Mutations of codon 61 of N-RAS (N2) have been reported in as many as 19% of follicular tumors

 

Medullary thyroid cancer (MTC)

  1. Accounts for 5–10% of thyroid cancers

  2. Develops in the C cells of the thyroid; has very little, if any, similarity to normal thyroid tissue

  3. Occurs with multiple endocrine neoplasia type 2 (MEN 2A and MEN 2B2), in familial medullary thyroid carcinoma (FMTC) and as a sporadic form (≈80% of cases are sporadic)

  4. Germline mutations in the RET (REarranged during Transfection) protooncogene cause hereditary MTC (MEN 2A, MEN 2B, and FMTC). In addition, up to 50% of patients with sporadic MTC have somatic RET mutations

  5. MEN 2B: RET mutations in codons 918, 883, or compound heterozygotes (V804M + E805K, Y806C ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MH Privacy Center Close